BioArctic
ISIN: SE0010323311 | Ticker: BIOA | LEI: 549300Y0OI2WVUNHLC33
Country: Sweden
BioArctic is a Swedish research intensive biopharma company aimed at developing new treatments that address the causes of disorders that affect the Central Nervous System. These types of treatments are commonly referred to as “disease modifiers”. They affect the underlying disease pathology and can hopefully stop or significantly delay disease progression. This is a large paradigm shift from today’s symptom-oriented therapies.
BioArctic’s proprietary technology platform, dedicated personnel, collaborations with leading academic research groups and the global pharma industry have made it possible to develop innovative treatments based on antibodies (immunotherapy) for neurodegenerative disorders.
Our main research areas are Alzheimer’s disease and Parkinson’s disease where there are large unmet medical needs. Today there are no treatments that can stop or slow down the progression of these diseases.
1992
HeadquartersWarfvinges väg 35, 11251 Stockholm – Sweden
| Line item in (sek) | 02.01.2020 | 01.01.2021 | 02.01.2021 | 01.01.2022 | 02.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|---|
| Assets | N/A | 1,050,313,000.00 | N/A | 897,730,000.00 | N/A | 858,307,000.00 |
| Noncurrent Assets | N/A | 41,953,000.00 | N/A | 35,944,000.00 | N/A | 37,466,000.00 |
| Property Plant And Equipment | N/A | 18,120,000.00 | N/A | 16,963,000.00 | N/A | 23,531,000.00 |
| Deferred Tax Assets | N/A | 452,000.00 | N/A | 608,000.00 | N/A | 596,000.00 |
| Other Noncurrent Financial Assets | N/A | 1,562,000.00 | N/A | 1,588,000.00 | N/A | 1,606,000.00 |
| Current Assets | N/A | N/A | N/A | 861,786,000.00 | N/A | 820,841,000.00 |
| Trade And Other Current Receivables | N/A | 0.00 | N/A | 2,839,000.00 | N/A | 0.00 |
| Other Current Receivables | N/A | 4,255,000.00 | N/A | 4,648,000.00 | N/A | 6,740,000.00 |
| Cash and cash equivalents | 999,940,000.00 | 999,940,000.00 | 848,405,000.00 | 848,405,000.00 | N/A | 805,386,000.00 |
| Equity And Liabilities | N/A | 1,050,313,000.00 | N/A | 897,730,000.00 | N/A | 858,307,000.00 |
| Equity | 974,497,000.00 | 907,299,000.00 | 907,299,000.00 | 788,676,000.00 | 788,676,000.00 | 786,241,000.00 |
| Issued Capital | N/A | 1,761,000.00 | N/A | 1,761,000.00 | N/A | 1,763,000.00 |
| Retained Earnings | N/A | 344,562,000.00 | N/A | 225,939,000.00 | N/A | 217,520,000.00 |
| Share Premium | N/A | 560,018,000.00 | N/A | 560,018,000.00 | N/A | 566,001,000.00 |
| Other Reserves | N/A | 958,000.00 | N/A | 958,000.00 | N/A | 958,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 907,299,000.00 | N/A | 788,676,000.00 | N/A | 786,241,000.00 |
| Noncurrent Liabilities | N/A | 34,293,000.00 | N/A | 7,785,000.00 | N/A | 1,182,000.00 |
| Deferred Tax Liabilities | N/A | 20,666,000.00 | N/A | 0.00 | N/A | N/A |
| Current Liabilities | N/A | 108,721,000.00 | N/A | 101,268,000.00 | N/A | 70,883,000.00 |
| Trade And Other Current Payables | N/A | 14,311,000.00 | N/A | 11,818,000.00 | N/A | 21,491,000.00 |
| Current Tax Liabilities Current | N/A | 0.00 | N/A | 0.00 | N/A | 0.00 |
| Other Current Liabilities | N/A | 3,576,000.00 | N/A | 3,919,000.00 | N/A | 5,427,000.00 |
| Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 62,347,000.00 | 23,146,000.00 | 228,291,000.00 |
| Employee Benefits Expense | 62,977,000.00 | 72,499,000.00 | 115,650,000.00 |
| Depreciation And Amortisation Expense | 11,013,000.00 | 13,107,000.00 | 14,633,000.00 |
| Other Expense By Nature | 23,370,000.00 | 24,852,000.00 | 33,015,000.00 |
| Finance Income | 7,000.00 | 194,000.00 | 7,025,000.00 |
| Finance Costs | 1,686,000.00 | 984,000.00 | 751,000.00 |
| Profit Loss Before Tax | -86,691,000.00 | -140,512,000.00 | -11,168,000.00 |
| Income Tax Expense Continuing Operations | -18,174,000.00 | -20,723,000.00 | 11,000.00 |
| Profit Loss From Continuing Operations | -68,517,000.00 | -119,789,000.00 | -11,179,000.00 |
| Profit (loss) | -85,012,000.00 | -139,723,000.00 | -17,442,000.00 |
| Profit Loss Attributable To Owners Of Parent | -68,517,000.00 | -119,789,000.00 | -11,179,000.00 |
| Line item in (sek) | 01.01.2021 | 02.01.2020 | 01.01.2022 | 02.01.2021 | 01.01.2023 |
|---|---|---|---|---|---|
| Profit (loss) | -85,012,000.00 | N/A | -139,723,000.00 | N/A | -17,442,000.00 |
| Adjustments For Decrease Increase In Other Operating Receivables | 23,086,000.00 | N/A | -5,122,000.00 | N/A | -2,414,000.00 |
| Adjustments For Increase Decrease In Other Operating Payables | 3,472,000.00 | N/A | 62,000.00 | N/A | 27,328,000.00 |
| Other Adjustments For Noncash Items | -19,991,000.00 | N/A | 5,230,000.00 | N/A | -41,234,000.00 |
| Cash Flows From Used In Operations | -92,341,000.00 | N/A | -140,457,000.00 | N/A | -31,638,000.00 |
| Interest Paid Classified As Operating Activities | -1,686,000.00 | N/A | -984,000.00 | N/A | -751,000.00 |
| Interest Received Classified As Operating Activities | 7,000.00 | N/A | 388,000.00 | N/A | 2,535,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | 12,473,000.00 | N/A | 4,386,000.00 | N/A | 12,746,000.00 |
| Other Inflows Outflows Of Cash Classified As Investing Activities | -51,000.00 | N/A | -27,000.00 | N/A | -18,000.00 |
| Cash Flows From Used In Investing Activities | -12,524,000.00 | N/A | -4,412,000.00 | N/A | -12,763,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | 6,598,000.00 | N/A | 7,389,000.00 | N/A | 8,793,000.00 |
| Dividends Paid Classified As Financing Activities | 0.00 | N/A | 0.00 | N/A | -5,985,000.00 |
| Cash Flows From Used In Financing Activities | -6,598,000.00 | N/A | -7,389,000.00 | N/A | -2,808,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | -111,463,000.00 | N/A | -152,257,000.00 | N/A | -47,209,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | -1,367,000.00 | N/A | 723,000.00 | N/A | 4,190,000.00 |
| Cash and cash equivalents | 999,940,000.00 | 999,940,000.00 | 848,405,000.00 | 848,405,000.00 | 805,386,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 08.11.23 | Eugen Steiner | Other | Buy | SEK 212,390.00 |
| 06.10.23 | Johanna Margareta Fälting | Other | Sell | SEK 2,800,000.00 |
| 27.07.23 | Cecilia Edström | Other | Buy | SEK 1,013,204.85 |
| 02.06.23 | Sten Mikael Moge | Other | Sell | SEK 164,400.00 |
| 31.05.23 | Oskar Bosson | Other | Sell | SEK 785,250.00 |
| 30.05.23 | Oskar Bosson | Other | Sell | SEK 924,235.00 |
| 21.05.23 | Johanna Margareta Fälting | Other | Other | SEK 627,000.00 |
| 19.05.23 | Sten Mikael Moge | Other | Sell | SEK 619,866.00 |
| 18.05.23 | Oskar Bosson | Other | Other | SEK 722,280.00 |
| 17.05.23 | Christer Möller | Other | Other | SEK 250,800.00 |
SE0010323311
LEI549300Y0OI2WVUNHLC33
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.